CytomX Therapeutics Market Sentiment

SPY769.95+0.04%QQQ724.17−0.66%BTC/USD82,151.41+0.72%DIA520.26+0.90%GLD380.85+1.29%TLT80.04+1.46%

Premium

CytomX Therapeutics Inc

CTMXNASDAQ

Trade with Public

$2.38

0.156.95%

Last update: Oct 15, 2:12 PM

$2.20

-0.03-1.35%

Overview News Earnings Forecast Events Price Targets FinancialsSentimentOwnership Compare Options Stock Report

CytomX Therapeutics Market Sentiment

Market sentiment signals for CytomX Therapeutics (CTMX): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 21.3% short float

Options Flow▲ 0.17 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

11 analysts

Options Flow (P/C)

0.17

More calls — Bullish

42 calls · 7 puts

Avg Consensus PT

$11

+344.4%

Highest Price Target

$16

+570.9%

Jefferies

Lowest Price Target

+50.5%

BMO Capital

Short Interest

21.3%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Aug 13, 2026	JP Morgan	Anupam Rama—	+361.2%	$12 → $11	Maintained	Overweight
Aug 10, 2026	Guggenheim	Michael Schmidt—	+487.0%	$15 → $14	Maintained	Buy
May 11, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+361.2%	$17 → $11	Maintained	Buy
Mar 23, 2026	Piper Sandler	Joseph Catanzaro—	+403.1%	$10 → $12	Maintained	Overweight
Mar 19, 2026	Barclays	Etzer Darout—	+570.9%	$10 → $16	Maintained	Overweight
Mar 18, 2026	Jefferies	Roger Song—	+570.9%	$8 → $16	Maintained	Buy
Mar 18, 2026	Guggenheim	Michael Schmidt—	+528.9%	$10 → $15	Maintained	Buy
Mar 17, 2026	Wedbush	Robert Driscoll—	+361.2%	$6 → $11	Maintained	Outperform
Mar 16, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+612.8%	$10 → $17	Maintained	Buy
Mar 16, 2026	JP Morgan	Anupam Rama—	+403.1%	$7 → $12	Upgrade	Neutral→Overweight
Mar 9, 2026	Guggenheim	Michael Schmidt—	+319.3%	$10 → $10	Maintained	Buy
Feb 4, 2026	Cantor Fitzgerald	Olivia Brayer—	+319.3%	$6 → $10	Maintained	Overweight
Feb 4, 2026	Barclays	Etzer Darout—	+319.3%	$8 → $10	Maintained	Overweight
Jan 20, 2026	Barclays	Etzer Darout—	+235.4%	$6 → $8	Maintained	Overweight
Jan 20, 2026	Guggenheim	Michael Schmidt—	+319.3%	$10	Initiate	Buy
Jan 20, 2026	Piper Sandler	Joseph Catanzaro—	+319.3%	$7 → $10	Maintained	Overweight
Nov 11, 2025	HC Wainwright & Co.	Mitchell S. Kapoor—	+319.3%	$5 → $10	Maintained	Buy
Oct 21, 2025	Barclays	Etzer Darout—	+151.6%	$4 → $6	Maintained	Overweight
Sep 22, 2025	Cantor Fitzgerald	Olivia Brayer—	+151.6%	$6	Initiate	Overweight
Sep 17, 2025	Barclays	Etzer Darout—	+46.8%	$4	Assumes	Overweight
Jul 31, 2025	Oppenheimer	Matthew Biegler—	+193.5%	$7	Initiate	Outperform
May 20, 2025	HC Wainwright & Co.	Mitchell Kapoor—	+109.6%	$5 → $5	Maintained	Buy
May 15, 2025	Piper Sandler	Joseph Catanzaro—	+109.6%	$3 → $5	Maintained	Overweight
May 15, 2025	HC Wainwright & Co.	Mitchell Kapoor—	+109.6%	$5 → $5	Upgrade	Neutral→Buy
Apr 14, 2025	Piper Sandler	Joseph Catanzaro—	+4.8%	$3 → $3	Maintained	Overweight